Titlebook: Kidney Cancer; Robert A. Figlin Book 2003 Kluwer Academic Publishers 2003 Staging.cancer.carcinoma.cell.genetics.kidney.minimally invasive

只看該作者 · 發(fā)表于 2025-3-25 14:06:35

Cancer Treatment and Researchhttp://image.papertrans.cn/k/image/542675.jpg

只看該作者 · 發(fā)表于 2025-3-25 15:57:10

978-1-4613-5083-5Kluwer Academic Publishers 2003

只看該作者 · 發(fā)表于 2025-3-25 23:01:27

Kidney Cancer978-1-4615-0451-1Series ISSN 0927-3042 Series E-ISSN 2509-8497

只看該作者 · 發(fā)表于 2025-3-26 03:52:16

只看該作者 · 發(fā)表于 2025-3-26 05:35:23

The Role of Systemic Chemotherapy in the Treatment of Kidney Cancerpproximately 10 months with a 3-year survival rate of about 10%.. RCC is typically described as chemotherapy (and radiation therapy) resistant. Most authors agree that biologic response modifiers (i e immunotherapy) represent standard first-line treatment for advanced RCC.

只看該作者 · 發(fā)表于 2025-3-26 08:52:28

Monoclonal Antibody Therapy of Kidney Cancer once RCC has metastasized, treatment options are very limited. This tumor is not radiosensitive, resistant to chemotherapy, and treatment with biological response modifiers (IL-2, IFN) leads to low response rates.

只看該作者 · 發(fā)表于 2025-3-26 13:23:05

https://doi.org/10.1007/978-1-4615-0451-1Staging; cancer; carcinoma; cell; genetics; kidney; minimally invasive surgery; molecular genetics; preventi

只看該作者 · 發(fā)表于 2025-3-26 19:09:41

		自動(dòng)登錄	找回密碼
密碼			To register

關(guān)于派博傳思			派博傳思旗下網(wǎng)站			友情鏈接
派博傳思介紹	公司地理位置	論文服務(wù)流程	影響因子官網(wǎng)	吾愛論文網(wǎng)	大講堂	北京大學(xué)	Oxford Uni.	Harvard Uni.
發(fā)展歷史沿革	期刊點(diǎn)評(píng)	投稿經(jīng)驗(yàn)總結(jié)	SCIENCEGARD	IMPACTFACTOR	派博系數(shù)	清華大學(xué)	Yale Uni.	Stanford Uni.
\|Archiver\|手機(jī)版\|小黑屋\| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-7 17:26
Copyright © 2001-2015 派博傳思京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved